Gjc2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GJC2 (Gap Junction Protein Gamma 2), also known as connexin 46.2 (Cx46.2), is a gap junction protein expressed primarily in the central and peripheral nervous system. Gap junctions formed by GJC2 allow direct cell-to-cell communication between glial cells, facilitating potassium buffering, metabolite transfer, and calcium signaling that are essential for proper myelination and white matter function. [1]
| Protein Name | GJC2 (Connexin 46.2) |
|---|---|
| Gene Symbol | GJC2 |
| Full Name | Gap Junction Protein Gamma 2 |
| UniProt ID | Q9NZA1 |
| Protein Length | 440 amino acids |
| Molecular Weight | 42.8 kDa |
| Cellular Localization | Plasma membrane (gap junctions) |
| Expression | Glial cells (oligodendrocytes, astrocytes) |
GJC2/Cx46.2 has the characteristic four-transmembrane domain connexin structure:
| Domain | Position | Function |
|---|---|---|
| N-terminus | 1-38 | Part of the channel pore, voltage sensing |
| TM1 | 39-61 | First transmembrane helix |
| Extracellular loop 1 | 62-103 | Mediates docking with neighboring hemichannels |
| TM2 | 104-126 | Second transmembrane helix |
| Cytoplasmic loop | 127-194 | Intracellular loop, regulatory functions |
| TM3 | 213-235 | Third transmembrane helix |
| Extracellular loop 2 | 236-278 | Mediates hemichannel docking |
| TM4 | 279-301 | Fourth transmembrane helix |
| C-terminus | 302-440 | Cytoplasmic tail, regulatory domain |
Six connexin proteins oligomerize to form a hemichannel (connexon), and two hemichannels from adjacent cells dock to form a complete gap junction channel.
GJC2 forms functional gap junction channels through:
GJC2 shows glial-specific expression patterns:
GJC2 performs essential gap junction functions in the nervous system:
GJC2 is essential for proper CNS myelination:
| Disease | Mechanism | Evidence |
|---|---|---|
| Pelizaeus-Merzbacher-like disease (PMLD) | Hypomorphic mutations cause severe hypomyelinization | OMIM 608803, confirmed |
| Primary Lymphedema | Lymphatic vessel dysfunction due to gap junction defects | Mutations in GJC2 |
| Refsum Disease | Possible disease modifier | Genetic studies |
| Multiple Sclerosis | Potential role in demyelination | Expression studies |
| ALS | Astrocyte gap junction dysfunction | Animal models |
| Autism Spectrum Disorder | Altered glial coupling | Genetic associations |
GJC2 as a therapeutic target:
Gjc2 knockout mice demonstrate:
Future research areas:
The study of Gjc2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.